Overview

NCI Definition [1]:
A pneumococcal conjugate vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae, used in children and studied in immunocompromised patients for the prevention of pneumococcal disease. The pneumococcal 13-valent conjugate vaccine contains capsular antigen polysaccharides derived from the S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F that are individually conjugated to a nontoxic diphtheria cross-reactive material (CRM) carrier protein (CRM197). Upon vaccination, pneumococcal 13-valent conjugate vaccine induces active immunization against 13 different serotypes of S. pneumoniae and protects against pneumococcal disease.

Pneumococcal 13-valent conjugate vaccine has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating pneumococcal 13-valent conjugate vaccine, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open).

Diffuse large B-cell lymphoma, hepatocellular carcinoma, and high grade B-cell lymphoma, not otherwise specified are the most common diseases being investigated in pneumococcal 13-valent conjugate vaccine clinical trials [2].

Drug Details

Synonyms [2]:
prevnar 13, prevenar13, pneumococcal 13-valent conjugate vaccine, pcv13 vaccine, pneumococcal 13-valent conjugate vaccine (product), prevenar 13, pneumococcal conjugate pcv 13, prevnar 13, pneumococcal 13-valent conjugate vaccine, pcv13 vaccine, pcv-13 vaccine, pcv 13, pneumococcal 13-valent conjugate vaccine, pneumococcal conjugate vaccine, 13 valent, pneumococcal 13-valent conjugate vaccine [va product]
NCIT ID [1]:
C97121
SNOMED ID [1]:
C-B6104

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.